SCHEMBL802269

SCHEMBL802269

Cc1ccccc1-c1cc(Nc2n[nH]c3ccc(F)cc23)c2c(n1)CCCC2

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GSK3A P49840 3/20 0.44
GSK3B P49841 3/20 0.44
FADS1 O60427 2/20 0.41
RIPK2 O43353 4/20 0.39
GAK O14976 1/20 0.37
LCK P06239 1/20 0.37
TGFBR1 P36897 1/20 0.37
KCNH2 Q12809 1/20 0.37
MAPK14 Q16539 1/20 0.37
RIPK3 Q9Y572 1/20 0.37
EGFR P00533 1/20 0.37
ACHE P22303 4/20 0.35
BCHE P06276 3/20 0.35
GRIN1 Q05586 3/20 0.35
GRIN2A Q12879 3/20 0.35
EPHA4 P54764 1/20 0.34
ULK1 O75385 1/20 0.34
ITK Q08881 1/20 0.34
KDM4E B2RXH2 1/20 0.33
ALDH1A1 P00352 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL802334 0.90 FADS1 (0.45) GSK3AGSK3BFADS1RIPK2GAK
SCHEMBL802329 0.89 VCP (0.38) FADS1EGFRACHEBCHEEPHA4
SCHEMBL805536 0.88 ACP1 (0.44) GSK3AGSK3BFADS1RIPK2GAK
SCHEMBL802031 0.83 GSK3A (0.45) GSK3AGSK3BFADS1RIPK2GAK
SCHEMBL802250 0.83 FADS1 (0.45) GSK3AGSK3BFADS1RIPK2GAK
SCHEMBL801639 0.79 GSK3A (0.50) GSK3AGSK3BFADS1RIPK2GAK
SCHEMBL802268 0.78 FADS1 (0.42) GSK3AGSK3BFADS1EGFRACHE
SCHEMBL802675 0.78 GSK3A (0.51) GSK3AGSK3BFADS1RIPK2GAK
SCHEMBL801665 0.78 FADS1 (0.51) GSK3AGSK3BFADS1RIPK2GAK
SCHEMBL12619795 0.78 ACP1 (0.42) FADS1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8633210-B2 Triazole compounds useful as protein kinase inhibitors VERTEX PHARMACEUTICALS INCORPORATED (US) 2014-01-21 US disclosed
US-20120071657-A1 TRIAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-03-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120071657-A1 TRIAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS GSK3B, GSK3A, CDK19 GSK3A 2/4885GSK3B 1/4885FADS1 3442/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.